David A. Pattison

5.5k total citations
82 papers, 1.4k citations indexed

About

David A. Pattison is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, David A. Pattison has authored 82 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 29 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Epidemiology. Recurrent topics in David A. Pattison's work include Prostate Cancer Treatment and Research (27 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Neuroendocrine Tumor Research Advances (20 papers). David A. Pattison is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Neuroendocrine Tumor Research Advances (20 papers). David A. Pattison collaborates with scholars based in Australia, United Kingdom and United States. David A. Pattison's co-authors include Rodney J. Hicks, Michael S. Hofman, Grace Kong, Tim Akhurst, Jason Callahan, Matthew J. Roberts, Paul Thomas, Richard W. Tothill, Louise Emmett and Amir Iravani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of Applied Physics.

In The Last Decade

David A. Pattison

75 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Pattison Australia	21	546	453	396	351	334	82	1.4k
Sabine Haufe Germany	17	653 1.2×	671 1.5×	445 1.1×	107 0.3×	515 1.5×	32	1.5k
H.-J. Biersack Germany	20	225 0.4×	579 1.3×	219 0.6×	304 0.9×	239 0.7×	80	1.4k
Vincenzo Allegri Italy	15	334 0.6×	417 0.9×	392 1.0×	90 0.3×	432 1.3×	32	1.1k
Frederik A. Verburg Netherlands	19	227 0.4×	415 0.9×	226 0.6×	419 1.2×	190 0.6×	82	1.2k
F. Courbon France	20	256 0.5×	386 0.9×	553 1.4×	166 0.5×	495 1.5×	84	1.4k
Frank I. Lin United States	20	222 0.4×	336 0.7×	160 0.4×	254 0.7×	160 0.5×	59	1.2k
J. Glaholm United Kingdom	19	364 0.7×	335 0.7×	297 0.8×	88 0.3×	172 0.5×	61	1.2k
Angela Spanu Italy	21	339 0.6×	676 1.5×	298 0.8×	182 0.5×	145 0.4×	104	1.3k
Steve Cho United States	18	408 0.7×	481 1.1×	155 0.4×	104 0.3×	265 0.8×	74	1.4k
Amir Kurtaran Austria	24	249 0.5×	527 1.2×	675 1.7×	169 0.5×	765 2.3×	62	1.7k

Countries citing papers authored by David A. Pattison

Since Specialization

Citations

This map shows the geographic impact of David A. Pattison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Pattison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Pattison more than expected).

Fields of papers citing papers by David A. Pattison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Pattison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Pattison. The network helps show where David A. Pattison may publish in the future.

Co-authorship network of co-authors of David A. Pattison

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Pattison. A scholar is included among the top collaborators of David A. Pattison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Pattison. David A. Pattison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pattison, David A., Grace Kong, Timothy Akhurst, et al.. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine Related Cancer. 32(6).

Roberts, Matthew J., Natasha Roberts, Anita Pelecanos, et al.. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research. 15(1). 92–92. 1 indexed citations

Azad, Arun, Mathias Bressel, Hsiang Tan, et al.. (2024). LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 35. S1255–S1256. 1 indexed citations

Rhee, Handoo, Sheliyan Raveenthiran, Anita Pelecanos, et al.. (2024). The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort. European Urology Focus. 10(5). 770–778. 4 indexed citations

Pattison, David A., J. Younger, Avinash Chikatamarla, et al.. (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology. 30(6). 2676–2691. 2 indexed citations

Emmett, Louise, Shalini Subramaniam, Megan Crumbaker, et al.. (2023). LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology. 34. S1325–S1325. 7 indexed citations

Lee, Sze Ting, Louise Emmett, David A. Pattison, et al.. (2022). The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. Journal of Nuclear Medicine. 63(6). 819–822. 12 indexed citations

Rhee, Handoo, Simon Wood, Sheliyan Raveenthiran, et al.. (2022). Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology Seminars and Original Investigations. 40(6). 276.e1–276.e9. 11 indexed citations

Li, Minmin, David Chan, Gonzalo Tapia Rico, et al.. (2022). Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Neuroendocrinology. 113(3). 281–288. 3 indexed citations

10.

Dhiantravan, Nattakorn, Louise Emmett, Anthony M. Joshua, et al.. (2021). UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol). British Journal of Urology. 128(3). 331–342. 40 indexed citations

11.

Roberts, Matthew J., Andrew Morton, Peter Donato, et al.. (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 48(2). 477–482. 66 indexed citations

12.

Thomas, Paul, et al.. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Internal Medicine Journal. 49. 27–27. 1 indexed citations

13.

Ladwa, Rahul, David A. Pattison, Matthew Burge, et al.. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). Neuroendocrinology. 106. 249–249. 1 indexed citations

14.

Hicks, Rodney J., Price Jackson, Grace Kong, et al.. (2018). ⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine. 60(6). 777–785. 110 indexed citations

15.

Ladwa, Rahul, David A. Pattison, Steven N. Goodman, et al.. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. Neuroendocrinology. 106. 251–251. 1 indexed citations

16.

Pattison, David A. & Rodney J. Hicks. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine Related Cancer. 24(6). R203–R221. 39 indexed citations

17.

Pattison, David A., et al.. (2017). Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging. Urology. 114. e1–e2. 6 indexed citations

18.

Kong, Grace, Simona Grozinsky‐Glasberg, Michael S. Hofman, et al.. (2017). Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism. 102(9). 3278–3287. 119 indexed citations

19.

Pattison, David A., Richard W. Tothill, Grace Kong, et al.. (2016). 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 16(1). 22–22. 126 indexed citations

20.

Pattison, David A. & Michael S. Hofman. (2015). Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics. 10(4). 461–476. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact